These results provide important information on key design parameters in the formulation of NO●-based therapeutics, and highlight the utility of a model-based approach for the analysis of dosing regimens.
Given the sources of beta-lactam pharmacokinetic variability highlighted, Ulldemolins and colleagues suggest a general approach to dosing of patients.
Then, we explored the accuracy of different computational approaches on dose calculation, including (I) direct Monte Carlo radiation transport using Raydose, (II) Kernel convolution using Philips Stratos, (III) local deposition algorithm, (IV) Monte Carlo technique (MCNP) considering a uniform activity distribution, and (V) MIRD Medical Internal Radiation Dosee) analytical approach.
A novel approach of low-dose corticosteroid was found to have beneficial effects on hemodynamics and outcome [ 7- 9].
Thus, the study design enabled us to use a regression analysis approach of DHA dose against expression of each gene that would enable identification of responses otherwise insensitive to normal pair-wise molecular comparisons, but potentially highly biologically relevant.
Therefore, the approach of fixed dose rate infusion, involving the administration of gemcitabine at a fixed rate over a prolonged period of time, has been studied in the clinical trial setting.
This trial was part of a novel approach to dose finding with drug combinations, in which the dose response of each component within the FDC was explored to confirm whether it is the same as the dose response when used as monotherapy.
A start-low go-slow approach towards dosing of warfarin is advised to avoid over-anticoagulation of patients with severe kidney dysfunction.
Based on these results, we suggest that with the approach of maximal carboplatin dose and low dose paclitaxel, it may be possible to create an active dose-dense platinum-focussed "scaffold" that can be used to feasibly integrate novel agents that target the reversal of platinum resistance [ 27].
After an overview of current approaches to dose-response assessment for pathogenic microorganisms, this paper discusses how KEDRF might be applied to pathogens, using Listeria monocytogenes and fetal listeriosis as an initial example.
Some methods and results are considered from the development and implementation of film-based approaches to dose verification and for external audits and also from initial studies of aSi EPIDs for dose verification and for in vivo dosimetry.
